Nektar Therapeutics

About Nektar Therapeutics

Nektar Therapeutics is dedicated to creating new medicines that address serious medical needs, leveraging cutting-edge chemistry and life-changing biology to bring hope to millions of patients. Their mission focuses on optimizing therapeutic benefits through expertise in polymer chemistry and advancing treatments for autoimmune disorders, chronic inflammatory conditions, and cancer by selectively modulating the immune system.

Products & Services

Medicines Marketed by Partners (U.S. and EU):Approved medicines marketed by partners in the U.S. and EU for various medical conditions.

Investigational Medicines:Medicines under research and development, part of the R&D pipeline.

REZPEG (NKTR-358):A novel therapy targeting autoimmune disorders.

PEG-CSF1:A therapy under development in the field of immunology.

TNFR-2:An immunology-focused therapy in the R&D pipeline.

Specialties

Polymer Chemistry Immune System Modulation Autoimmune Disorders Chronic Inflammatory Conditions Cancer Treatment T Regulatory Cells Interleukin-15 (IL-15) Pathway

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 115000000 MR: - FA: $115 million FAN: 115000000	D: 2025-07-02 FD: 2025-07-02	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2025-07-01 FD: 2025-07-01	4 investors
3	RT: Private Placement T: - FT: Private Placement	A: 30000000 MR: - FA: $30 million FAN: 30000000	D: 2024-03-04 FD: 2024-03-04	1 investors

Public Offering Latest

2025-07-02

$115.0M

4 investors (Pro only)

Public Offering 2025-07-01

$100.0M

Private Placement 2024-03-04

$30.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Robert B. Chess

Chairman of the Board, Nektar Therapeutics, Chairman, BigHat Biosciences and Lead Director, Twist Biosciences

J

Jeff Ajer

Former Executive Vice President and Chief Commercial Officer, BioMarin

D

Diana M. Brainard, M.D.

Former Chief Executive Officer, AlloVir, Inc.

R

R. Scott Greer

Managing Director, Numenor Ventures, LLC

H

Howard W. Robin

President & Chief Executive Officer

R

Roy A. Whitfield

Former Chairman and Chief Executive Officer, Incyte Corporation

View 10 more team members with Pro

Unlock Full Team Directory

Recent News